Enterprise Therapeutics (TMEM16A Potentiator Portfolio) Overview

  • Status
  • Acquired/​Merged

  • Latest Deal Type
  • Asset Purch.

  • Financing Rounds
  • 1

Enterprise Therapeutics (TMEM16A Potentiator Portfolio) General Information

Description

Portfolio of TMEM16A potentiator program including ETD002. The portfolio is focused towards treating people with cystic fibrosis and has the potential to benefit people with other severe respiratory diseases characterized by excessive mucus congestion.

Contact Information

Ownership Status
Acquired/Merged
Financing Status
Corporate Backed or Acquired
Corporate Office
  • Brighton
  • England, United Kingdom
Primary Industry
Buildings and Property
Other Industries
Biotechnology
Drug Discovery
Acquirer
Corporate Office
  • Brighton
  • England, United Kingdom

Want detailed data on 11M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

Enterprise Therapeutics (TMEM16A Potentiator Portfolio) Valuation & Funding

Deal Type Date Amount Valuation/
EBITDA
Post-Val Status Debt

This information is available in the PitchBook Platform. To explore Enterprise Therapeutics (TMEM16A Potentiator Portfolio)‘s full profile, request access.

Request a free trial

Enterprise Therapeutics (TMEM16A Potentiator Portfolio) Former Investors

Investor Name Investor Type Holding Investor Since Participating Rounds Contact Info

This information is available in the PitchBook Platform. To explore Enterprise Therapeutics (TMEM16A Potentiator Portfolio)‘s full profile, request access.

Request a free trial

Enterprise Therapeutics (TMEM16A Potentiator Portfolio) FAQs

  • Where is Enterprise Therapeutics (TMEM16A Potentiator Portfolio) headquartered?

    Enterprise Therapeutics (TMEM16A Potentiator Portfolio) is headquartered in Brighton, United Kingdom.

  • What industry is Enterprise Therapeutics (TMEM16A Potentiator Portfolio) in?

    Enterprise Therapeutics (TMEM16A Potentiator Portfolio)’s primary industry is Buildings and Property.

  • Is Enterprise Therapeutics (TMEM16A Potentiator Portfolio) a private or public company?

    Enterprise Therapeutics (TMEM16A Potentiator Portfolio) is a Private company.

  • What is the current valuation of Enterprise Therapeutics (TMEM16A Potentiator Portfolio)?

    The current valuation of Enterprise Therapeutics (TMEM16A Potentiator Portfolio) is .

  • What is Enterprise Therapeutics (TMEM16A Potentiator Portfolio)’s current revenue?

    The current revenue for Enterprise Therapeutics (TMEM16A Potentiator Portfolio) is .

  • Who are Enterprise Therapeutics (TMEM16A Potentiator Portfolio)’s investors?

    Enterprise Therapeutics, Epidarex Capital, Forbion, IP Group, and Novartis Venture Fund are 5 of 7 investors who have invested in Enterprise Therapeutics (TMEM16A Potentiator Portfolio).

  • When was Enterprise Therapeutics (TMEM16A Potentiator Portfolio) acquired?

    Enterprise Therapeutics (TMEM16A Potentiator Portfolio) was acquired on 07-Oct-2020.

  • Who acquired Enterprise Therapeutics (TMEM16A Potentiator Portfolio)?

    Enterprise Therapeutics (TMEM16A Potentiator Portfolio) was acquired by Roche.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read more
  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process